A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

NCT06890611 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Bimagrumab
DRUG: Tirzepatide
DRUG: Bimagrumab + Tirzepatide Coformulation

Sponsor

Eli Lilly and Company